# Tau Takes Center Stage as a July Alzheimer's Readout Looms - The Neuro & Alzheimer's Pipeline - Week of July 5, 2026 > The Neuro & Alzheimer's Pipeline for the week of July 5, 2026. The podcast tape swung from anti-amyloid launches to tau, featuring a Voyager operator interview, a dated BIIB080 July readout, and a maturing blood-diagnostics debate, but still no operator color on the marketed drugs. ## The Neuro & Alzheimer's Pipeline ### Week of July 5, 2026: Tau Takes Center Stage as a July Alzheimer's Readout Looms --- After a dead-quiet week on the podcast tape, the conversation woke up, and it walked right past the anti-amyloid launches to the target everyone's been circling for a decade: **tau**. We got a genuinely substantive operator interview, a Parkinson's-and-FDA-reform deep dive, and two smart clinician discussions on the diagnostics plumbing. What we *still* didn't get: a single word of hard launch color on Kisunla, Leqembi, or IQLIK. Two weeks running now, the specialist desks are silent on the numbers you actually trade. That gap is itself the story. ## TL;DR - **Tau is having a moment.** Voyager's CEO (ex-Biogen R&D chief) laid out the amyloid-triggers-tau "forest fire" model and flagged that Biogen's tau ASO **BIIB080 has read out, with data due at a July conference**, a concrete, near-term catalyst. Two big anti-amyloid early-treatment studies (Lilly and Biogen/Eisai) read out "within the next year or so" and could decide whether treating tau is even necessary. - **Diagnostics keeps maturing, and the sell-side thesis is getting more nuanced.** Two FDA-approved blood tests now exist, pTau-217 is "widely clinically available," and clinicians are drawing a hard line: triaging vs. confirmatory, symptomatic-only, and a real false-positive problem in kidney disease and obesity. The TAM (>45M Americans potentially "preclinical") is enormous; the infrastructure to act on it is not there. - **Still no operator pipeline color** on LLY Kisunla, BIIB/Eisai Leqembi/IQLIK, Roche trontinemab/bepranemab, or ABBV neuro. Flagged, not dressed up. ## What's New **The most useful operator interview in weeks, and it's about tau, not amyloid.** On [Business Of Biotech](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjeU46Mhon5utFPkVDp5hhU3FfIY4hLRC-2Bl7rAlBrtxP-2F449zC8Z94bN0g7vAZ5wgf2lVG-2FOK73PLV66Ma-2BzF8ioZRO9AoODtTzH5OEACoB-2BA-3D-3Deqc-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUdlcUZY3Ogit5vpmGiTLFhyGrZ6IG4pGxBXQv9c8TYi83mQGOHxfnWUi3ZNEZJiZ2kbo7lkbisSmOGzXygLlZyFEXfOxR-2FdOv8mvR3hAy1GITSPn1E1g4PlojpwsEpEHiq4RZyTTHlMZflPKfNBdwIUlzIMv4xL70PiT3PAkFAGg-3D-3D) (June 29), Voyager Therapeutics CEO **Al Sandrock** (who ran R&D at Biogen through the aducanumab era, OPERATOR/INSIDER) gave the clearest amyloid-vs-tau framing you'll hear: "I think they're both important… it's like a forest fire. The tau is the forest fire, but the match might be amyloid." Everyone accumulates a little misfolded tau with normal aging, confined to the entorhinal cortex; amyloid is what triggers it to *spread*. His punchline for the franchise debate: "if you really want to treat Alzheimer's more effectively, you got to go after tau." *Why it moves numbers:* this is the intellectual scaffolding for every tau bet on the board, and it reframes anti-amyloid drugs as the trigger-remover, not the cure. **A concrete July catalyst: BIIB080.** Same episode, same speaker: Sandrock noted that Biogen's tau antisense oligonucleotide, **BIIB080, "has just read out and we're going to see the results at the conference in July."** He was candid about its Achilles heel: it "requires intrathecal injections… every six months," a lumbar puncture that would "overwhelm the medical system" at scale. *Why it matters:* a dated, near-term data drop for a Biogen pipeline asset, plus a built-in commercial-friction bear case. Watch the July readout. **Voyager's own tau shots on goal, two milestones this year.** Sandrock (OPERATOR): the gene therapy **VY-1706** (a one-time IV that makes cells express a tau-lowering siRNA) got **FDA IND clearance "a couple of weeks ago"** (early June), with first patient enrollment expected "in the second half of this year." Voyager's tau *antibody* has been in the clinic ~2 years and will produce a **tau-PET imaging readout in H2 2026** showing whether it impedes tau spread. He was blunt on economics: business development is "one of the key ways we can get cash," the deals bring "non-dilutive revenue," and Voyager retains opt-in rights of "40% U.S." on one program and "50%" on another. On commercialization: "we're definitely gonna need to partner it. Alzheimer's disease is too big." > "There may be some patients who, if you treat the amyloid, you need nothing else… There may be others where you need to add the tau treatments." > > Al Sandrock, on why combination therapy may be the endgame **The diagnostics bar just got higher.** Two clinician discussions sharpened the blood-test thesis. On [Keeping Current CME](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhqRNIMNYgyCRnNUUJqV79VKEN6Xr9nII6mgCpnqEb3obJbrn2ZRQevbnDsnZk2hv-2Fy-2FspImBcbZII5-2BWqv1Id1Ys4reYlNIvt-2BRAuIUz4O8g-3D-3DWPCB_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUdlcUZY3Ogit5vpmGiTLFhyGrZ6IG4pGxBXQv9c8TYiynpHCiayv9bfNHPc9ttYZvlvUwxwrTIwWlGwTFDCmAUFPzY-2FcN5UaJjE4S6Q3Y3C0kbwknlUMZj34lMmKWuq35wCmSWNNP7R6iT-2FtRUZY7PPOfPF2nx8AIKmHEGkgVGqQ-3D-3D) (June 29), the faculty confirmed **two FDA-approved blood tests now exist** (a pTau-181 *triaging* test, negative rules out, positive needs follow-up, and an amyloid-ratio *confirmatory* test), while **pTau-217 alone is "widely clinically available"** but not standalone FDA-approved. The caveats that matter for pricing: sensitivity/specificity data come "from specialized clinics… not at the population level," renal dysfunction and obesity "could alter these plasma biomarkers" and drive false positives, and a positive result in a cognitively normal person can trigger denial of "long-term care insurance, life insurance, disability insurance." On [Brain Talk](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgeUDMC-2BA9wUunhYIto1fJdyv6A1upY0WuZca7MgES87CNjirJz4Zh5Y9zKjGBw8zHMSlEudNGV6xloylp2VSyH-2BMgc-2FpepAIMbIeTejZlS1Q-3D-3DmZl4_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUdlcUZY3Ogit5vpmGiTLFhyGrZ6IG4pGxBXQv9c8TYi9-2Bp8P7LgrnkL88FAHV1d1i6UMpR8D-2FvlUY4mNKf0WS6qnDgUgtK8tJK07BmHDW9lyg-2Bg1n-2Fc6dzSx2ffN95huyYs88N00wqzZzw6huppGTVCe7hTUrIDJHsHstUEje5sA-3D-3D) (July 1), UC Irvine trialist **Dr. Joshua Grill** (OPERATOR) put a number on the TAM ("more than 45 million Americans may qualify for preclinical Alzheimer's disease diagnoses") and immediately flagged the bottleneck: there aren't enough neurologists to disclose those results one-on-one, pushing the field toward phone or even "AI-derived avatar" disclosure. He also cautioned blood biomarkers "can even change on a circadian pattern," and that only anti-amyloid drugs "clearly do change" them. ## The Debate *Does sub-Q dosing + blood biomarkers + broadening coverage turn anti-amyloid into a multi-billion franchise, or do modest efficacy, ARIA, and diagnostic bottlenecks keep uptake structurally weak while the tau bets stay unproven?* **Bull:** The scientific case is compounding, not stalling. Sandrock's framing (amyloid as the match, tau as the fire) implies removing amyloid *early* could keep tau bottled up; the Lilly and Biogen/Eisai early-treatment studies reading out within a year could prove exactly that. A >45M-person preclinical TAM sits underneath, and blood tests are the cheap front door to reach it. **Bear:** The whole edifice depends on plumbing that isn't built. Blood tests only work in symptomatic patients today, misfire in kidney disease and obesity, and there aren't enough specialists to disclose a positive result, let alone treat 45 million people. The best tau asset with dated near-term data, BIIB080, needs a spinal tap every six months. And Sandrock himself concedes the definitive combination-therapy question won't resolve until those early-treatment readouts land. Net: the debate tilted *scientifically* toward tau this week, but nothing moved the near-term commercial needle for the marketed drugs. The silence on launch metrics (two weeks now) is a soft negative. ## Stocks in Play - **VYGR (Voyager):** *Bull:* two tau shots on goal (gene therapy + antibody), non-dilutive partnering with opt-in economics (40–50% U.S. rights). *Bear:* early clinical, cash-constrained small-cap, "most programs fail," will need a partner for any AD Phase 3. *Next catalyst:* VY-1706 first patient H2 2026; antibody **tau-PET readout H2 2026**. (Business Of Biotech, June 29) - **BIIB:** *Bull:* tau optionality beyond Leqembi via BIIB080. *Bear:* intrathecal q6-month delivery is a commercial anchor; no Leqembi ramp color this week. *Next catalyst:* **BIIB080 data at a July conference**. (Business Of Biotech, June 29) - **LLY / Eisai:** *Bull:* the early-treatment study could expand the anti-amyloid TAM into prevention. *Bear:* it could also show tau still needs treating; zero launch color on the tape. *Next catalyst:* early-treatment study readout "within the next year." (Business Of Biotech, June 29) - **RHHBY (Roche) / PRTA (Prothena):** Roche's Parkinson's partner asset **prasinezumab** (alpha-synuclein, with Prothena) is in Phase 3. No trontinemab/bepranemab coverage. (BioCentury, June 29) - **ANVS (Annovis):** buntanetap in Phase 3 for Parkinson's. (BioCentury, June 29) - **QTRX, Fujirebio, Roche, LabCorp/Quest:** *Bull:* two FDA-approved tests + widely available pTau-217 = volume. *Bear:* validation gap outside specialty clinics, false positives, insurance-discrimination overhang. (Keeping Current CME, June 29; Brain Talk, July 1) ## Read-throughs - **Blood diagnostics (QTRX, Fujirebio, Roche Elecsys, LabCorp/Quest):** the theme is maturing from "is it real" to "how is it used": triaging vs. confirmatory, symptomatic-only, false positives in renal/obese patients. Volume tailwind, but the standard-of-care is being written around the *validated, reimbursed* assay. (Keeping Current CME, June 29; Brain Talk, July 1) - **PET imaging (LNTH, GEHC):** tau-PET is now the read-out tool for tau *drug trials* (Sandrock uses it as Voyager's de-risking modality), supporting a research/clinical-trial demand thesis distinct from diagnostic scans. Watch, separately, [Tomorrow's Cure](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjFqxAGcwYz4xD2PwJ1S1-2FAC-2FKpUX-2FTr-2BBlooAiRsAuf86Xh-2BKzcomDG7wuBoiiKwekru8ZEALZGq-2BeaS5noHtkT-2BJoqng6o2N4u84ckVLMOQ-3D-3DYdMH_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUdlcUZY3Ogit5vpmGiTLFhyGrZ6IG4pGxBXQv9c8TYi7WqDc3KvDp7OnheYjWK-2FcalRzeDUxrculXfLHKyLQQLZf6zIvgfiPfCGnfo83QG9Ca40-2FrrnWQx0IOi7dWpoI4tO9fAqEKMeYPvBCmKEEKIVm5fzeQw17cCheYuNS-2BH4g-3D-3D) (July 1), where Mayo researchers described AI-plus-retinal-photography hitting "90-plus percent accuracy" distinguishing AD from controls, a cheap, scalable screening angle that, if validated, competes with both PET and blood over the long run. Early-stage, not investable, but a structural watch-item for the imaging names. - **Broader CNS / Parkinson's:** [BioCentury This Week Ep. 374](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjWD6oxjo4MeQctMPfyA8DVPFap6JEAvSPUa1RIhKNYN-2BgzaUIipR8tlioi2nK-2BNuuJMCpNt9qJEJX3xdpIZB9o7VAfJVLK7vFHJBUtWqAjug-3D-3DKZ34_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUdlcUZY3Ogit5vpmGiTLFhyGrZ6IG4pGxBXQv9c8TYiwiCVGrR4KDyKQa86MG58qD1Ta2S4h7ZR-2B0GZbpbSYPdfMEuoqsSdzoC5tJxs9QhK-2Fr1wDGuyTtFnqq3-2BCnEBkny8zoY6OCpoawZxRnrbGk4InrpNlkLSoZbrpowv7KNDQ-3D-3D) (June 29) flagged the first cell therapy for Parkinson's: Sumitomo's allogeneic product got conditional authorization in Japan in March (now Phase 1/2 in the U.S.), with Bayer/BlueRock's bemdaneprocel in Phase 3, plus FDA's "Operation Trial Blazer" push to speed U.S. trials. A regenerative-medicine and regulatory read-through worth tracking. (PUNDIT/analyst commentary.) - **Tau science (preclinical):** a Cell paper (June 29) flagged on [Science News Daily](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOil9XkBNPjz0NP-2BQnoHxGQSMQLjLV6I3tN7mSTP03IXhMQnCaKQTwpt9Pvts1xLLMxelLVmy8kKG9vCSdmZx8HJH7AaTPFIS0y4iEpbDISEhA-3D-3DnTIh_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUdlcUZY3Ogit5vpmGiTLFhyGrZ6IG4pGxBXQv9c8TYi3HV-2FsSBSD-2BB2AGyxK5F1cVsf102X7c7IY1KEMtiANLBZpCJ-2FAy7QcreWUuenXjRD2oLM8TRz30M-2F2rCDLbIbkUz0X71M4NIzOvkbwGwJk9lwkkjqAgqQL1s-2B10pZMkBaQ-3D-3D) (June 30) showed the ARC protein mediates tau spread between neurons via extracellular vesicles in mice, mechanistically consistent with Sandrock's spread model, but years from a target. - **Infusion centers / specialty pharmacy (OPCH):** no coverage this week. ## What Changed vs Last Week Last week was diagnostics-only and pessimistic: a clinician warning that pTau-217 was going direct-to-consumer with a validation gap, plus a candid "we are where AZT was for HIV" scorecard on anti-amyloid. **This week the axis shifted from amyloid disappointment to tau opportunity:** a real operator interview, a dated BIIB080 July catalyst, Voyager's two 2026 milestones, and preclinical tau-spread science all pointing the same direction. The diagnostics thread continued but got more sophisticated, from "commoditization" to the operational reality of triaging-vs-confirmatory tests and a 45M-patient disclosure bottleneck. **What did *not* change:** still zero operator commentary on Kisunla starts, Leqembi/IQLIK persistence, or payer/CMS coverage friction. That's now a two-week blank on the metrics that actually move the marketed franchises.